RE: Nice article25 Oct 2024 07:17
Clinical lead and co-author of the publication, Professor Dmitry Pshezhetskiy (University of East Anglia; ME/CFS specialist doctor, Royal Cornwall Hospitals NHS Trust) said: "The EpiSwitch platform has already delivered robust biomarkers and commercial tests for immuno-oncology (CiRT) and prostate cancer (PSE). I was directly involved in the development of the PSE test and have had the opportunity to appreciate the power of the EpiSwitch platform. I believe EpiSwitch is the one platform that is prepared to take on another heavy burden, ME/CSF, which has impacts affecting patients, healthcare and society. This is the tool that will develop the first robust diagnostic test and give us actionable insights for the effective treatment."